Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Invested Capital (2021 - 2025)

Historic Invested Capital for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $11.6 million.

  • InMed Pharmaceuticals' Invested Capital rose 3805.85% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 3805.85%. This contributed to the annual value of $13.4 million for FY2025, which is 4593.02% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Invested Capital is $11.6 million, which was up 3805.85% from $13.4 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Invested Capital registered a high of $15.2 million during Q3 2021, and its lowest value of -$9.6 million during Q3 2023.
  • Its 5-year average for Invested Capital is $10.0 million, with a median of $11.1 million in 2024.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 18701.07% in 2023, then surged by 18765.26% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Invested Capital (Quarter) stood at $14.2 million in 2021, then grew by 0.77% to $14.3 million in 2022, then decreased by 10.9% to $12.8 million in 2023, then crashed by 51.6% to $6.2 million in 2024, then surged by 87.49% to $11.6 million in 2025.
  • Its last three reported values are $11.6 million in Q3 2025, $13.4 million for Q2 2025, and $7.0 million during Q1 2025.